Cart
sales@molnova.com
Notum pectinacetylesterase-1
CAS No. 460727-10-0
Notum pectinacetylesterase-1( —— )
Catalog No. M35314 CAS No. 460727-10-0
Notum pectinacetylesterase-1 is a Notum Pectinacetylesterase inhibitor with IC50 < 0.025 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 257 | In Stock |
|
| 2MG | 166 | In Stock |
|
| 5MG | 256 | In Stock |
|
| 10MG | 375 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 776 | In Stock |
|
| 100MG | 1042 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2102 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNotum pectinacetylesterase-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionNotum pectinacetylesterase-1 is a Notum Pectinacetylesterase inhibitor with IC50 < 0.025 μM.
-
DescriptionNotum pectinacetylesterase-1 is a potent inhibitor of notum pectinacetylesterase. Notum pectinacetylesterase-1 can be used for the research of disorders affecting the bone.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number460727-10-0
-
Formula Weight334.42
-
Molecular FormulaC14H14N4O2S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS(CC(NC=1C=C(C)ON1)=O)C2=C3C(SC(C)=C3C)=NC=N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Barbosa, et al. Inhibitors of notum pectinacetylesterase and methods of their use. Patent. US20120065200.
molnova catalog
related products
-
Methyl ganoderenate ...
Methyl ganoderenate D is a natural product for research related to life sciences.
-
yuanamide
yuanamide is an alkaloid compound.
-
Amylin, amide, human
Amylin, a 37-amino acid polypeptide that is structurally related to calcitonin, is secreted from the B cells of the pancreas. Amylin has anoretic effects in rats. Amylin may be responsible for the etiology of insulin resistance of type II diabetes mellitus through its modulation of peripheral effects of insulin.
